Ayumu Hosokawa
Miyazaki, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications
WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2).
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: December 22, 2025
Postoperative Outcomes and Strategic Refinement in Intraductal Papillary Mucinous Neoplasm Management: A Single Academic Cancer Center Experience.
Journal: Cancer diagnosis & prognosis
Published: November 04, 2025
Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer.
Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer.
Journal: Anticancer research
Published: July 28, 2025
Feasibility of endoscopic response evaluation after induction chemotherapy for determining treatment strategies in esophageal cancer: a post hoc analysis of the CROC trial.
Journal: Esophagus : official journal of the Japan Esophageal Society
Published: July 14, 2025
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study.
Journal: Therapeutic advances in medical oncology
Published: June 26, 2025
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
Journal: Frontiers in oncology
Published: May 11, 2025
A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS).
Journal: Future oncology (London, England)
Published: May 08, 2025
Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting.
Journal: Journal of gastroenterology
Published: January 29, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).
Journal: Therapeutic advances in medical oncology
Published: November 21, 2024
Last Updated: 09/26/2026